Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp increased its stake in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 28.3% in the 2nd quarter, HoldingsChannel reports. The firm owned 86,401 shares of the company’s stock after buying an additional 19,035 shares during the quarter. Bank of New York Mellon Corp’s holdings in Actinium Pharmaceuticals were worth $639,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ATNM. Sanders Morris Harris LLC acquired a new stake in Actinium Pharmaceuticals in the 1st quarter worth about $78,000. Virtu Financial LLC raised its stake in shares of Actinium Pharmaceuticals by 319.2% in the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after acquiring an additional 62,459 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares in the last quarter. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Price Performance

Shares of NYSE:ATNM opened at $1.84 on Tuesday. Actinium Pharmaceuticals, Inc. has a one year low of $1.33 and a one year high of $10.24. The firm has a market cap of $54.80 million, a P/E ratio of -1.08 and a beta of 0.14. The firm’s fifty day moving average is $3.56.

Actinium Pharmaceuticals (NYSE:ATNM) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. As a group, research analysts expect that Actinium Pharmaceuticals, Inc. will post -1.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ATNM has been the subject of a number of recent analyst reports. HC Wainwright lowered their price objective on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Maxim Group reduced their price objective on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. StockNews.com cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 18th. Finally, B. Riley lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $16.00 to $2.00 in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.40.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).